The analysis of genetic variability in CYP27B1 and its effect on risk of multiple sclerosis (MS) has yielded conflicting results. Here we describe a study to genetically characterize CYP27B1 and elucidate its role on MS risk in the Canadian population. Sequencing CYP27B1 failed to identify mutations known to cause loss of enzymatic activity, however genotyping of p.R389H in cases and controls identified the mutation in one multi-incident family (allele frequency = 0.03%) in which the p.R389H mutation segregates with disease in five family members diagnosed with MS, thus providing additional support for CYP27B1 p.R389H in the pathogenicity of MS.
Introduction
Although several genes and loci have been associated with an increased risk of developing multiple sclerosis (MS), the identification of specific genetic variants within these loci which could account for the observed increased susceptibility has been challenging. Cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) p.R389H is one of a few variants with a known biological outcome located within a locus associated with increased risk of MS (ANZgene, 2009). The original description of this variant in MS patients arose from an exome sequencing study characterizing disease associated loci in 43 MS probands from Canada (Ramagopalan et al., 2011) . The identification of the p.R389H mutation (rs118204009) in one sample led to the evaluation of 10 nonsynonymous variants known to cause CYP27B1 loss of function, and one novel variant in 3046 parents-affected child trios, 422 parent-affected sib pairs and 1873 ethnically matched healthy individuals. In total, five CYP27B1 variants were identified in MS patients, the most prevalent being p.R389H with a carrier frequency of 0.67%. After performing segregation analysis, the authors concluded that these functional variants were overtransmitted in affected family members and overrepresented in MS patients (odds ratio = 4.7), suggesting that a loss of functional activity in CYP27B1 confers an increased risk of MS.
In contrast to this initial report, replication studies found no evidence of an increased frequency of CYP27B1 p.R389H in large cohorts of MS patients of European descent (Ban et al., 2013; Barizzone et al., 2013; Cortes et al., 2013; Reinthaler et al., in press ). Ban et al. genotyped rs118204009 in 495 multi-incident families, 2092 single affected families, 4594 additional cases, and 3583 controls from Norway, the United Kingdom, and the United States. This analysis identified the mutant allele of p.R389H at a frequency of 0.07% and 0.06% in patients and controls, respectively (Ban et al., 2013) . Barizzone et al. identified p.R389H at a frequency of 0.05% in 2608 MS patients and 1987 controls from Italy and Belgium (Barizzone et al., 2013) . In addition to the lack of association, sequencing CYP27B1 in 134 probands from multi-incident families failed to identify any of the previously reported variants resulting in a loss of enzymatic activity or any novel risk variants. Similarly, the p.R389H mutation was not identified in 999 MS patients and 397 controls from Austria (Reinthaler et al., in press) or 3269 MS patients and 3577 healthy controls of European descent (Cortes et al., 2013) . Thus these studies did not support a role for CYP27B1 in MS susceptibility. To determine whether the association observed in the initial study is limited to the Canadian population we assessed the frequency of p.R389H and evaluated the presence of loss of function mutations in CYP27B1 in MS patients and controls from Canada.
Materials and methods
All samples were collected through the longitudinal Canadian Collaborative Project on the Genetic Susceptibility to Multiple Sclerosis (CCPGSMS) between 1997 and 2008 (Sadovnick et al., 1998 . The ethical review boards at the University of British Columbia approved the study, and all participants provided informed consent. All patients were diagnosed with MS according to Poser criteria (Poser et al., 1983 ) prior to 2001 , or McDonald criteria thereafter (McDonald et al., 2001 Polman et al., 2005) . A total of 1647 MS probands and 849 Journal of Neuroimmunology 266 (2014) 64-66 
